Sort by

Send to

Choose Destination

Links from PubMed

Items: 11


Association Between KCNJ11 Gene E23K Polymorphism and Body Composition Together with its Response to Endurance Training.

Duoqi Z, Qing H, Yang H, Yanchun L, Yi X, Li W.

Open Biomed Eng J. 2015 Jun 9;9:121-5. doi: 10.2174/1874120701509010121. eCollection 2015.


Replication of KCNJ11 (p.E23K) and ABCC8 (p.S1369A) Association in Russian Diabetes Mellitus 2 Type Cohort and Meta-Analysis.

Sokolova EA, Bondar IA, Shabelnikova OY, Pyankova OV, Filipenko ML.

PLoS One. 2015 May 8;10(5):e0124662. doi: 10.1371/journal.pone.0124662. eCollection 2015.


Genetics of type 2 diabetes-pitfalls and possibilities.

Prasad RB, Groop L.

Genes (Basel). 2015 Mar 12;6(1):87-123. doi: 10.3390/genes6010087. Review.


Population specific impact of genetic variants in KCNJ11 gene to type 2 diabetes: a case-control and meta-analysis study.

Phani NM, Guddattu V, Bellampalli R, Seenappa V, Adhikari P, Nagri SK, D Souza SC, Mundyat GP, Satyamoorthy K, Rai PS.

PLoS One. 2014 Sep 23;9(9):e107021. doi: 10.1371/journal.pone.0107021. eCollection 2014. Review.


Quantitative assessment of the effect of KCNJ11 gene polymorphism on the risk of type 2 diabetes.

Qiu L, Na R, Xu R, Wang S, Sheng H, Wu W, Qu Y.

PLoS One. 2014 Apr 7;9(4):e93961. doi: 10.1371/journal.pone.0093961. eCollection 2014.


Effect of genetic polymorphisms on the development of secondary failure to sulfonylurea in egyptian patients with type 2 diabetes.

El-Sisi AE, Hegazy SK, Metwally SS, Wafa AM, Dawood NA.

Ther Adv Endocrinol Metab. 2011 Aug;2(4):155-64. doi: 10.1177/2042018811415985.


Pharmacogenetics of Anti-Diabetes Drugs.

Distefano JK, Watanabe RM.

Pharmaceuticals (Basel). 2010 Aug 1;3(8):2610-2646.


Gene-gene interactions lead to higher risk for development of type 2 diabetes in an Ashkenazi Jewish population.

Neuman RJ, Wasson J, Atzmon G, Wainstein J, Yerushalmi Y, Cohen J, Barzilai N, Blech I, Glaser B, Permutt MA.

PLoS One. 2010 Mar 26;5(3):e9903. doi: 10.1371/journal.pone.0009903.


Impact of the Pro12Ala polymorphism of the PPAR-Gamma 2 gene on metabolic and clinical characteristics in the Palestinian type 2 diabetic patients.

Ereqat S, Nasereddin A, Azmi K, Abdeen Z, Amin R.

PPAR Res. 2009;2009:874126. doi: 10.1155/2009/874126. Epub 2009 Oct 25.


Pharmacogenetics: potential role in the treatment of diabetes and obesity.

Vella A, Camilleri M.

Expert Opin Pharmacother. 2008 May;9(7):1109-19. doi: 10.1517/14656566.9.7.1109. Review.


Combining information from common type 2 diabetes risk polymorphisms improves disease prediction.

Weedon MN, McCarthy MI, Hitman G, Walker M, Groves CJ, Zeggini E, Rayner NW, Shields B, Owen KR, Hattersley AT, Frayling TM.

PLoS Med. 2006 Oct;3(10):e374.

Items per page

Supplemental Content

Support Center